The head-to-head battle between the epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer drugs (NSCLC) Leclaza and Tagrisso has carried on to competition of each drug's combination therapy regimens. This month, the U.S. Food and Drug Administration (FDA) approved Leclaza+Rybrevant as a first-line treatment for EGFR-positive NSCLC. This is the first time a targeted therapy plus targeted therapy combination has been approved.

Tagrisso was approved in Korea and the U.S. this year after confirming its efficacy in combination with platinum-based chemotherapy. While attention is focused on whether combination therapies will find a place in the first-line treatment market for EGFR-mutated NS